Skip to main content

InnoSer partners with CR2O to offer an integrated drug discovery to clinical trials pipeline.

Researchers benefit from a comprehensive service offering, spanning early-stage discovery to phase I-IV trials, with meticulous planning and access to specialized services, aiming to set a new standard for excellence in the industry.

Diepenbeek, Belgium and Maarsen, Netherlands, March 20th 2024: InnoSer, a pioneering leader in pre-clinical research services, is delighted to announce its strategic partnership with CR2O, a full-service clinical CRO specialised in managing complex clinical trials. Through this collaboration, InnoSer and CR2O can offer an integrated drug discovery and development platform that seamlessly progresses high-value clinical candidates from pre-clinical to clinical research and market authorization.

The strategic collaboration between InnoSer and CR2O bridges a critical gap between pre-clinical and clinical development, two areas plagued by high failure rates, escalating costs, and lengthy timelines. By enabling a more integrated and holistic approach to drug development, InnoSer and CR2O empower their clients to increase success rates, enhance efficiency, and reduce the time-to-market of their ground-breaking treatments. This not only facilitates a smoother process between the preclinical to clinical transition but also aligns with InnoSer and CR2O’s commitment to innovation and excellence in bringing new therapies to patients in need.

Through these combined efforts, clients of InnoSer and CR2O will benefit from an integrated service offering, encompassing everything from early-stage drug discovery services to the execution of phase I-IV clinical trials. This synergy allows for a more agile and collaborative research journey, ensuring that every phase is meticulously planned and executed with clinical and regulatory implications in mind. Furthermore, the combined expertise of both organizations will grant researchers access to a broader range of specialized services and optimized strategies for advancing drug candidates. These services include, but are not limited to, toxicology, pharmacology, preclinical program management, CMC advice and management, regulatory strategy and clinical operations.

In selecting CR2O as our strategic partner, we aim to provide our clients with critical regulatory insights earlier on in their discovery journey by leveraging over a decade of clinical knowledge,” Jan Bartels, Chief Executive Officer of InnoSer International explains. “This partnership underscores our shared desire to contribute innovation and efficiency to advance patient care, ensuring that together, we set a new standard for excellence in the biopharmaceutical contract research services industry.

Hadil Es-Sbai, Chief Executive Officer of CR2O, comments: “We see the need to solve the persistent problem of the fragmented approach to R&D. We are therefore pleased that through our partnership with InnoSer, we can now offer our customers end-to-end, fully integrated, and validated drug development pathways. This partnership allows us to provide a streamlined approach, aligning all aspects of the development process”.

Looking ahead, InnoSer and CR2O are committed to driving innovation in the drug development sector. By combining their resources and expertise, the two companies aim to set a new standard for excellence, providing their clients with increased confidence across the development lifecycle by de-risking activities and reducing associated costs.

About InnoSer

Founded in 2012, InnoSer is an innovative and dynamic CRO supporting pre-clinical development of drugs from its facilities in Belgium and the Netherlands. InnoSer supports its customers in the critical steps of their drug development journey with well characterized in vitro and in vivo disease models in addition to general drug development services, allowing to uncover valuable insights into the mode of action, pharmacokinetics, safety, and efficacy of investigational compounds.

About CR2O

CR2O, a full-service CRO for public and biopharma organisations, combines strong scientific leadership and operational excellence to conduct innovative clinical trials. Over the past decade, the company has built extensive experience managing complex clinical development programs and phase I-IV clinical trials. CR2Os ecosystem integrates end-2-end expertise to advance new therapies from bench to bedside. The company’s cross-functional teams, including Non-Clinical, Clinical, CMC, and Regulatory experts, apply their hands-on experience to accelerate product development and ensure credible datasets.

For more information, please contact:
Kris Motmans
Chief Business